Document Detail


Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
MedLine Citation:
PMID:  21088813     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Studies comparing the safety and tolerability of biological therapies for psoriasis in the long-term and in daily clinical practice are lacking. Most published studies are of selected patients with short-term (3-6 months) follow-up. We performed a retrospective cohort study of 103 patients in order to describe the frequency and the clinical features of adverse events, and to evaluate and compare the tolerability and safety of efalizumab, etanercept, infliximab, and adalimumab in clinical practice. A total of 136 courses of biological therapies were administered, with a mean duration of 16 months/patient; 55 patients received efalizumab, 45 etanercept, 33 infliximab, and 3 adalimumab. Infliximab had an incidence rate ratio of suspension due to severe adverse events 5.9 times (95% confidence interval (95% CI) 1.9-18, p < 0.001) higher than etanercept and 9.8 times (95% CI 3.2-30.1, p < 0.001) higher than efalizumab. Safety profiles for efalizumab and etanercept were more favourable than for infliximab. Concerning tolerability, we found that more patients responded to infliximab, but long-term tolerability was higher for both efalizumab and etanercept due to the better safety profile and a higher compliance to therapy.
Authors:
Alexandra M G Brunasso; Matteo Puntoni; Camilla Salvini; Chiara Delfino; Pero Curcic; Andra Gulia; Cesare Massone
Related Documents :
18802713 - Extension limitation and deviation of fingers by the scarred junctura tendinum: a case ...
19793213 - Corticosteroid injections, eccentric decline squat training and heavy slow resistance t...
18425953 - Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta dermato-venereologica     Volume:  91     ISSN:  1651-2057     ISO Abbreviation:  Acta Derm. Venereol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-25     Completed Date:  2011-04-20     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0370310     Medline TA:  Acta Derm Venereol     Country:  Sweden    
Other Details:
Languages:  eng     Pagination:  44-9     Citation Subset:  IM    
Affiliation:
Department of Environmental Dermatology, Medical University of Graz, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents / adverse effects,  therapeutic use*
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Dermatologic Agents / adverse effects,  therapeutic use*
Female
Humans
Immunoglobulin G / adverse effects,  therapeutic use
Male
Middle Aged
Psoriasis / drug therapy*
Receptors, Tumor Necrosis Factor / therapeutic use
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Dermatologic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/efalizumab; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spontaneous miscarriages and infant deaths among female farmers in rural South Africa.
Next Document:  [Complication following embolization of a meningioma].